Department of Surgical Oncology, Princess Margaret Cancer Centre/Mount Sinai Hospital, Toronto, ON, Canada.
Department of Surgery, University of Toronto, Toronto, ON, Canada.
Ann Surg Oncol. 2021 Nov;28(12):7873-7888. doi: 10.1245/s10434-021-09654-z. Epub 2021 Apr 14.
Retroperitoneal soft tissue sarcomas comprise a heterogeneous group of rare tumors of mesenchymal origin that include several well-defined histologic subtypes. In 2015, the Transatlantic Australasian RPS Working Group (TARPSWG) published consensus recommendations for the best management of primary retroperitoneal sarcoma (RPS). Since then, through international collaboration, new evidence and knowledge have been generated, creating the need for an updated consensus document.
The primary aim of this study was to critically evaluate the current evidence and develop an up-to-date consensus document on the approach to these difficult tumors. The resulting document applies to primary RPS that is non-visceral in origin, with exclusion criteria as previously described. The relevant literature was evaluated and an international group of experts consulted to formulate consensus statements regarding the best management of primary RPS. A level of evidence and grade of recommendation were attributed to each new/updated recommendation.
Management of primary RPS was considered from diagnosis to follow-up. This rare and complex malignancy is best managed by an experienced multidisciplinary team in a specialized referral center. The best chance of cure is at the time of primary presentation, and an individualized management plan should be made based on the 29 consensus statements included in this article, which were agreed upon by all of the authors. Whenever possible, patients should be enrolled in prospective trials and studies.
Ongoing international collaboration is critical to expand upon current knowledge and further improve outcomes of patients with RPS. In addition, prospective data collection and participation in multi-institution trials are strongly encouraged.
腹膜后软组织肉瘤是一组起源于间叶组织的罕见肿瘤,包括多种明确的组织学亚型。2015 年,跨大西洋澳大拉西亚 RPS 工作组(TARPSWG)发布了原发性腹膜后肉瘤(RPS)最佳治疗管理的共识建议。此后,通过国际合作,产生了新的证据和知识,需要更新共识文件。
本研究的主要目的是批判性地评估现有证据,并制定一份关于这些困难肿瘤治疗方法的最新共识文件。该文件适用于起源于非内脏的原发性 RPS,排除标准如前所述。评估了相关文献,并咨询了一组国际专家,就原发性 RPS 的最佳治疗管理达成共识声明。为每个新/更新的建议赋予了证据水平和推荐等级。
从诊断到随访,对原发性 RPS 的管理进行了考虑。这种罕见且复杂的恶性肿瘤最好由经验丰富的多学科团队在专门的转诊中心进行管理。在原发性表现时治愈的机会最大,应根据本文中包含的 29 条共识声明制定个体化的管理计划,所有作者均同意这些声明。在可能的情况下,应将患者纳入前瞻性试验和研究中。
持续的国际合作对于扩展现有知识并进一步改善 RPS 患者的预后至关重要。此外,强烈鼓励前瞻性数据收集和参与多机构试验。